Stocks rose Tuesday as investors considered earnings and an unexpected drop in orders for durable goods.» Read More
Brent Wilsey has a shopping list for the new year. The president of San Diego-based Wilsey Asset Management is urging investors to take a serious look at undervalued stocks -- and he offered CNBC viewers plenty of choices.
The seven biggest stories in my sectors in 2007? Avandia, Dendreon, Pfizer, Biogen were just a few of the topics that made this a fascinating year for the pharmaceuticals and biotechnology industries.
So, it didn't take long after my Genentech blog entry got posted yesterday for me to receive an email and a voicemail from a Genentech spokesperson requesting a "clarification" on my take regarding the latest chapter in the Avastin vs. Lucentis brouhaha. I think I'm being spun.
Most of my PR and professional contacts send Christmas cards, but for the past two years the boutique Wall Street firm, Rodman & Renshaw, has sent me heavy metal piggy banks. I assume the company sends them to its clients as well.
Cramer makes the call on viewers' favorite stocks.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
You can trade legally options "like an insider" -- if you stay alert and watch market momentum. Jon Najarian, co-founder of OptionsMonster.com and frequent guest on CNBC's "Fast Money," offered his wisdom on how to do it -- and which options look the hottest right now.
Eli Lilly announced this morning that Chairman and CEO Sidney Taurel is retiring as CEO on March 31st next year. He will stay on as Chairman and on April Fool's Day Chief Operating Officer John Lechleiter will take over as CEO. Investors, at least in early trading, seem to like the choice.
Shares of biotech behemoth Amgen are trading at a new intra-day low in the early going this morning after the company announced new data on its developmental osteoporosis drug late Friday. The Phase 3, or late-stage, study was designed to see if the twice-a-year injectable drug strengthened the bones of women with a certain type of breast cancer.
Earlier this week I blogged about Amgen's negative test results for its anemia drug Aranesp in breast cancer. The studies showed the drug may have caused tumors to grow and death. This morning it almost seems like there's a delayed market reaction.
Although the stock movement this morning is not reflecting it, the latest developments in Amgen and Genentech's efforts to come up with new treatments for breast cancer are emblematic of the opposite direction these California-based biotech behemoths and rivals are headed.
In 1990, Amgen was the risky-but-profitable biotech of choice. Today, its stand-in is Onyx Pharmaceuticals.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
In a filing with the SEC, Countrywide reports that it's one ratings cut away from junk...and a whole lotta trouble. I keep waiting for the sky to fall in Calabasas. It isn't. I live near Countrywide headquarters in Calabasas, Calif., out in Thousand Oaks, where Countrywide Bank is based.
The warning labels have been strengthened on anemia drugs made by Amgen Inc and Johnson & Johnson to reflect concerns they may increase the risk of heart attacks, stroke and death, the companies and U.S. regulators said on Thursday.
Buying in tech stocks could lift the market again Wednesday, but Merrill Lynch earnings hang in front of the opening bell like a dark cloud. Or should we say Merrill's report of losses. The firm is scheduled to report third quarter numbers between 7:30 and 8 a.m., and analysts are forecasting a loss of $0.45 per share.
Lots of late news from the drug makers. CNBC’s Mike Huckman has the latest.
Amgen's third-quarter earnings rose from a year ago and beat forecasts. The biotechnology firm reported a profit of $1.18 billion, or $1.08 a share, on sales of $3.6 billion.
On a day when the markets are selling off, shares of the world's biggest biotech company--by sales--are holding their own. There are a few things that could be buoying Amgen's stock. The company won a huge patent battle yesterday, it reports earnings after the closing bell today and an analyst has upgraded the stock to "Outperform".
Shares in the world's second biggest drug company, GlaxoSmithKline, are giving back all of yesterday's gains in early trading this morning. That's because sales of its embattled diabetes drug, Avandia and other Avandia-related products took a huge dive in the third quarter. Down 48% in the U.S. from the same time last year.
Stocks ended broadly higher amid continued strength in the tech sector, which gained following Research in Motion's deal to distribute BlackBerry smartphones in China, along with strong earnings reported by Apple.
A Boston jury Tuesday found that the patents on Amgen's top-selling anemia drugs are valid, blocking Roche from launching a rival medicine in the United States and sending Amgen shares up more than 2 percent.